Buradasınız

Anasayfa » Content

Katlarda Sisplatin ile Oluşturulan Gastrik Distansiyoıı ve Buna Bağlı Histopatolojik Değişiklikler Üzerine Sıvı Elektrolit Tedavisinin Etkisi

The Effect of Fluid and Electrolyte Management on Experimental Gastric Distantion with Cisplatin and Subsequent Histopathological Alterations in Rats

Journal Name:

  • Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1999

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Cisplatin, which is an organic platinum derivative is an anti-neoplastic agent that functions by cross-binding double helix of DNA molecule. Ototoxicity, peripheral neuropathy, muscle cramps, loss of appetite, nausea, vomiting and hepatic toxicity are some of the known side effects of cisplatin, the most important one being acute tubular necrosis. In this study, the changes that cisplatin causes in the gastrointestinal tract were investigated. Twenty one rats (Sprague Dawley) were used as 3 groups each including seven animals. % 09 NaCl solution (2 cc) and cisplatin (5 mg/kg) were given intraperitoneally to the first (control) and second group of animals while the third group receivedIVfluidtreatment (% 0.9 NaCl + ringer lactate solutions) through a catheterized jugular vein in addition to IP cisplatin (5 mg/kg). After seven days, blood samples were drawn from the animals for hematological and biochemical tests and they were subsequently sacrificed. Tissue samples were taken from stomach, small and large intestines of all animals. Macroscopically, gastric dilatation were observed in 4 of the rats in the second group. It was also observed in this group that gastric wall had become quite thin macroscopically while microscopic examination revealed almost complete loss of mucosa, regression of muscular layer and consequent membranous appearance of gastric wall. None of these changes were observed in the first and third groups. The absence of pathological changes in the third group is thought to be due to IV fluid treatment
Bookmark/Search this post with
Abstract (Original Language): 
Organik platin türevi olan sisplatin, DNA çift-zincirinde çapraz bağlanma yaparak etki gösteren bir antineoplastik ajandır. Ototoksisite, periferal nöropati, kas krampları, iştahsızlık, bulantı, kusma, iştahsızlık ve hepatik toksisite sisplatin 'in bilinen yan etkileridir. En önemli yan etkisi ise akut tübüler nekroz ve glomerüler fıltrasyon bozukluğudur. Bu çalışmada sisplatin 'in gastrointestinal sistemde ne tür histopatolojik değişiklikler oluşturduğu araştırıldı. Her biri yedi adet hayvandan oluşacak şekilde 21 adet Sprague Dawley rat üç gruba ayrıldı. Intraperitoneal yoldan; kontrol grubuna % 0.9 NaCl solüsyonu (2 cc), II. gruba 5 mg/kg sisplatin, III. gruba 5 mg/kg sisplatin + kateterize edilmiş juguler venden sıvı-elektrolit (% 0.9 NaCl + ringer laktat solüsyonu) verildi. Yedi gün sonra raflardan hemogram ve biyokimyasal testler için kan alınıp hayvanlar sakrifiye edildi. II. gruptaki rafların dördünde gastrik diiatasyon görüldü. Tüm gruplardan mide, ince barsak ve kolon örnekleri alınarak histopatolojik inceleme yapıldı. II. gruptaki rafların özellikle mide duvarının makroskopik olarak belirgin derecede inceldiği, mikroskopik incelemede ise mide mukozasının tamamen ortadan kalktığı, muskuler tabakanın çok inceldiği, sonuç olarak mide duvarının membranöz bir karakter kazandığı gözlendi. Grup I ve III 'te bu gözlemlere rastlanmadı. Sisplatin'e bağlı olarak oluşan bu yan etkinin
FULL TEXT (PDF): 
PDF icon arastirmax-katlarda-sisplatin-ile-olusturulan-gastrik-distansiyoii-buna-bagli-histopatolojik-degisiklikler-uzerine-sivi-elektrolit-tedavisinin-etkisi.pdf
  • 3
1-4
  • Turkish

REFERENCES

References: 

1-Hardman JG, Limbird LE,
Gilman
AG. Goodman&Gilman 's The Pharmacological Basis of Therapeutics. 9* Edition. International Edition.
4
Philadelphia, Mc Graw Hill, 1996; 786 -802.
2-Kayaalp
O. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji. Yedinci Baskı. Ankara: 1994; 123-47.
3-Roelofs EJ,
Wagener
DJ, Conray T,
Wils J, Burghouts JT, Fickers M, de Graeff A Lalisang F, Paillot B. Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-PJ in advanced gastric cancer. Ann Oncol 1993; 4(5): 426-8.
4- Chai JS, Lee KH, Ann MJ, Lee JS, Lee JH, Zcrng DY. Suh CW, Kim SW, Kim WG, Kim JC, Kim SK, Park KC, Lee MS, Kim SH. A randomized trial comparing cisplatin plus 5-jluorouracil with or without levamisole in operable gastric cancer. Korean J Intern Med 1997; 12(2): 155-62.
5-LoRusso P, Pozdur R, Redman BG, Kinzie J, Vaitkevicius V. Low-dose continuous infusion 5-jluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma. Am J Clin Oncol 1989; 12(6): 486-90.
6- Wang Y, Aggarwal SK. Effects of cisplatin ant taxol on inducible nitric oxide synthase, gastrin and somatostatin in gastrointestinal toxicity. Anticancer Drugs 1997; 8(9): 853-8.
7-Lee KE, Kubota T, Sawamura M, Kadowaki K Effect of metoclopramide on gastric distension and lethal toxicity of cisplatin in mice. Gan To Kagaku Ryoho 1986; 13(5): 1911-4.
8-Asbury RF, Blessing JA, Soper JT. A Gynecologic Oncology Group phase U study of amonqfide (NSC #308847) in squamous cell carcinoma of the cervix. Am J Clin Oncol 1994; 17(2): 125-8.
9-Aggarwal SK, San Antonio JD, Sokhansanj A, Miller C. Cisplatin-induced peptic ulcers, vagotomy, adrenal and calcium modulation. Anticancer Drugs 1994; 5(2): 177-93.
10-Srivastava RC, Farookh A Ahmad N, Misra M, Hasan SK, Husain MM. Evidence for the involvement of nitric oxide in cisplatin-induced toxicity in rats. Biometals 1996; 9(2): 139-42.

Thank you for copying data from http://www.arastirmax.com